Bull, Bear & Beyond – Mendus: executive interview

Mendus is an immuno-oncology company specialising in the field of allogeneic dendritic cell biology. It has two clinical-stage assets, vididencel and ilixadencel, both of which are off-the-shelf cell-based vaccines, designed to improve survival outcomes for cancer patients. Mendus is developing the lead programme, vididencel, as a maintenance therapy for acute myeloid leukaemia (AML). The company recently presented encouraging long-term survival data from the ADVANCE II trial, a Phase II trial evaluating vididencel as a single-agent treatment for AML patients with measurable residual disease following chemotherapy. Preparations are underway for pivotal studies aimed at market registration of vididencel based in combination with oral azacitidine, currently the only approved AML maintenance treatment. Mendus aims to be pivotal-stage ready by H225.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.